Europe Biodefense Market size crossed USD 3.8 billion in 2021 and is predicted to expand at a CAGR of 7.6% from 2022 to 2028.

Rapid technological advancement such as nanotechnology and advanced biothreat detector devices is the major factors that accelerate the market growth. For instance, with the introduction of advanced biosensor technologies it has become easier to identify and distinguish between microorganism and pathogen. Similarly, advancement in genome engineering has offered the ability to modify bacteria and viruses at the molecular level.

Get more details on this report - Request Free Sample PDF

In addition, key companies are focusing on introducing new bio-threat detection technologies. For instance, the BBI detection IMASS device contains a coded test strip that can detect up to eight biological threat agents. Recently developed biological threat detection devices deliver rapid results and increase demand. Moreover, technological advances in the biotechnology sector in the European economy will have a positive impact on biodefense market demand in Europe. Advances in biotechnology have enabled the development of high-quality attenuated and subunit vaccines. They are commonly used to treat viral and bacterial infections caused by the unexpected release of the virus.  

Europe Biodefense Market, By Product

Get more details on this report - Request Free Sample PDF

The vaccines product segment held around USD 2.5 billion revenue in 2021, owing to wide availability of vaccines for various disease such as HPV (human papillomavirus), Hib disease (Haemophilus influenzae type b) and hepatitis B. Additionally, rising investments in developing vaccines and increased government support for vaccine development are expected to impel the market growth.

Furthermore, Bacillus anthracis is a gram-positive bacterium that causes zoonotic disease such as anthrax and is one of the most used bioterrorist weapons. These spores are most preferred because they are easily released into the environment when added to food, water, powders, and sprays. They can survive long periods of time in the environment and are easily found in nature (soil, plants, or water). According to the NCBI, B. anthracis is classified as a Level 1 biological agent because it is easily transmitted from person to person and can have significant public health implications.

Europe Market, By Country

The UK biodefense market was valued at USD 987 million in 2021, due to the rising prevalence of infectious diseases in UK and growing awareness about the availability of vaccines and advanced devices. For instance, according to UK Government as of October 24, 2021, there were 3,419 suspected and 401 confirmed cases of Lassa fever in Nigeria. A total of 79 deaths have been reported, with a mortality rate of 19.7 percent. To address biosecurity risks, the UK government focusing on publishing an action plan for the Biological Security Strategy and establishing a dedicated National Centre for Biosecurity, to serve as a center of expertise on the full spectrum of biological risks facing the UK.

Competitive Industry Landscape

Major players involved in the Europe biodefense market include Alexeter Technologies, LLC, Altimmune, ANP Technologies, Bavarian Nordic, BioFire Defense (bioMérieux SA), Biosearch Technologies, Bruker Detection, Elusys Therapeutics, Emergent BioSolutions, Ichor Medical Systems, Inc., Nanologix, New Horizon Diagnostic Corp., and SIGA Technologies among others.

These companies have adopted various strategies such as product launches, collaborations, distribution agreements, and acquisitions that have helped them in sustaining the competition and gain significant position in the market. For instance, in January 2022, SIGA Technologies received SIGA’s Marketing Authorisation Application (MAA) for oral tecovirimat for the treatment of smallpox. This strategic move will help the company to enhance its revenue growth.